WeTrials
Recruiting

Phase 1/2 Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

What is this study?

This study is testing a new experimental messenger RNA therapy called mRNA-4359, both by itself and alongside other common cancer-fighting immunotherapy drugs. The main goal is to see how safe this treatment is and how well it helps the body's immune system target and fight advanced solid tumors.

Who can participate?

You might be able to join if you are 18 or older with advanced skin cancer (melanoma) or lung cancer that has progressed despite previous treatments. There are specific health requirements regarding past therapies, current medications, and tumor types that the study team will review with you.

What will happen?

Participants will receive the study treatment, which may include the mRNA therapy alone or combined with other immunotherapy drugs like pembrolizumab, ipilimumab, or nivolumab. Your health, side effects, and tumor response will be closely monitored by the medical team throughout the process.

Where and when?

This study is currently recruiting patients at multiple locations in the United States, including sites in California and Colorado. Your care team can help you find the most convenient location and let you know if spots are open.

Key Points
  • 1Tests a new messenger RNA therapy designed to boost the immune system against cancer
  • 2May involve receiving the study drug alone or combined with standard immunotherapy drugs
  • 3Currently actively recruiting patients with advanced solid tumors at specific U.S. locations

No related links yet

Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Advanced Solid Tumors

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.